SCHEMBL2501113

SCHEMBL2501113

C=C[C@H](c1cccc(O)c1)C(C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.49
▸ HIF1A Q16665 4/20 0.49
▸ KDM4E B2RXH2 3/20 0.49
▸ KYNU Q16719 1/20 0.43
▸ ADRB1 P08588 2/20 0.42
▸ ADRA1A P35348 2/20 0.42
▸ MIF P14174 1/20 0.42
▸ HTR2A P28223 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.39
▸ AKR1C3 P42330 1/20 0.39
▸ AKR1C2 P52895 1/20 0.39
▸ PTGS2 P35354 3/20 0.38
▸ ADRB2 P07550 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ ADRB3 P13945 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ ADRA2B P18089 1/20 0.37
▸ ADRA2C P18825 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10013089 1.00 LMNA (0.49) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL2501303 1.00 LMNA (0.49) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL10013090 1.00 LMNA (0.49) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL16871060 0.88 ADRB1 (0.42) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL16871044 0.88 ADRB1 (0.42) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL16871243 0.87 LMNA (0.40) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL16871055 0.87 LMNA (0.40) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL16871496 0.86 ADRB1 (0.45) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL16871645 0.86 ADRB1 (0.45) LMNAHIF1AKDM4EKYNUADRB1
SCHEMBL11071174 0.83 LMNA (0.53) LMNAKDM4EALDH1A1PTGS2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
Send feedback